Navigation Links
Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
Date:6/19/2013

zing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development with partners when and where appropriate.

Presently, Pharmacyclics has two product candidates in clinical development and several preclinical molecules in lead optimization. The Company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements, including our expected liquidity position and timing of the receipt of certain milestone payments, and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in thi
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
2. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
3. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
4. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
5. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
6. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
7. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
8. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
9. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
10. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
11. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 Across the global ... meeting challenges in clinical development, market education, and regulatory ... the Medical Affairs function is expected to increase in ... According to research by benchmarking firm, ... a group dedicated to Medical Affairs. Among companies in ...
(Date:3/27/2015)... , March 27, 2015 /PRNewswire/ - Medicure Inc. (the ... Directors has approved the grant of an aggregate of ... employees and consultants of the Company pursuant to the ... set to expire on the tenth anniversary of the ... the third anniversary of the date of grant and ...
(Date:3/27/2015)... VICTORIA, Texas , March 27, 2015  Victoria Vein ... removal services with the Astanza Duality laser in ... of vein disease as well as advanced laser treatments for ... are entering the tattoo industry to provide more services for ... Surgery has helped many Victoria residents ...
Breaking Medicine Technology:Medical Affairs Capabilities Expanding in Emerging Marketplaces 2Victoria Vein And Surgery Clinic Uses Advanced Astanza Duality Tattoo Removal Technology 2
... Sept. 27, 2011 Masimo ... that findings from a new study published in the ... noninvasive and continuous hemoglobin (SpHb®) monitoring has absolute and ... hemoglobin measurement with additional advantages.  Study highlights that "the ...
... the United States Food and Drug Administration ("FDA") said its ... fold increase risk of blood clots for women who use ... The safety of Yaz and Yasmin is the subject ... of Common Pleas Judge Sandra Mazer Moss, Coordinating Judge of ...
Cached Medicine Technology:Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients 2Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients 3Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients 4Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients 5Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients 6FDA Issues Safety Communication Regarding Increased Risk of Blood Clots with Certain Birth Control Pills 2
(Date:3/28/2015)... March 28, 2015 Early surgery may ... Type V AC joint injuries, according to new research ... at the American Orthopaedic Society for Sports Medicine’s ( ... duty faster when surgery was not performed. , The ... receiving surgical treatment and 17 receiving non-surgical therapy. Of ...
(Date:3/28/2015)... San Francisco, California (PRWEB) March 28, 2015 ... search for original 1960's Who psychedelic concert posters. The Who ... Flushing, New York on August 2, 1968. According to Hawley, ... 1969 playing many concert halls and college campuses. Perhaps the ... their performance with Jim Morrison and the Doors on August ...
(Date:3/28/2015)... 28, 2015 Aureus Medical Group ... including physical therapy jobs, has announced that it ... Physical Therapy Association Annual Conference to be held ... Hotel in Columbus, OH. , The OPTA ... exhibits with products and services. , Representatives ...
(Date:3/28/2015)... The "Petrick Sustainable Health System" ... After 18 years of research and experience with patients ... Dr. Jon Petrick is excited to be launching his ... the immediate benefits of this radical new system are ... strength of the immune system, faster healing of injuries, ...
(Date:3/28/2015)... March 28, 2015 ARDX will sponsor the ... 12pm -3pm at the Chesapeake Conference Center in Chesapeake, Virginia. ... an empowering event for women in the Hampton Roads region. ... Stories of Women’s Lives. Women grow stronger through sharing ... other. This year the WWC™ theme is T-talk where ...
Breaking Medicine News(10 mins):Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2
... Consensus Guideline Reached For Quantitative Polymerase Chain ReactionSALT LAKE ... and the American Association for Clinical ... guideline for a key laboratory method called qPCR (or ... of international scientists representing the medical and research fields. ...
... AdCare Health Systems, Inc. (NYSE AMEX: ADK ... and management company today reported financial results for its ... December 31, 2008 were $24,793,294 as compared to $23,667,756 ... The improvement was primarily due to increased rental charges ...
... alerting capabilities, delivering meaningful performance measurements and relevant operational data ... ... Plano, TX (PRWEB) March 31, 2009 -- ... - Corepoint Decisions . Corepoint Health,s latest product ...
... 31 Hanger Orthopedic Group, Inc. (NYSE: HGR ) ... operations for the first quarter ended March 31, 2009, on ... release announcing the results for the first quarter ended March ... of the market. The conference call is scheduled to begin ...
... provider of advanced, high-volume, document and payment processing ... signed an exclusive service provider agreement with iVu ... early detection of cancer and other disease states. ... BancTec,s growing Multi-Vendor Services Group."BancTec,s Multi-Vendor Services Group ...
... League biologist who researches viruses to determine how and why ... of Houston April 2. The lecture is free and ... University associate professor of ecology and evolutionary biology, will speak ... the Science and Engineering Classroom Building Auditorium. His talk ...
Cached Medicine News:Health News:International Scientists Secure Quality in Molecular Diagnostics 2Health News:International Scientists Secure Quality in Molecular Diagnostics 3Health News:AdCare Health Systems, Inc. Reports Financial Results for 2008 2Health News:AdCare Health Systems, Inc. Reports Financial Results for 2008 3Health News:AdCare Health Systems, Inc. Reports Financial Results for 2008 4Health News:AdCare Health Systems, Inc. Reports Financial Results for 2008 5Health News:AdCare Health Systems, Inc. Reports Financial Results for 2008 6Health News:AdCare Health Systems, Inc. Reports Financial Results for 2008 7Health News:AdCare Health Systems, Inc. Reports Financial Results for 2008 8Health News:AdCare Health Systems, Inc. Reports Financial Results for 2008 9Health News:Corepoint Health Launches New Product Suite Focused on Enhancing Healthcare Operations & Metrics 2Health News:Corepoint Health Launches New Product Suite Focused on Enhancing Healthcare Operations & Metrics 3Health News:Corepoint Health Launches New Product Suite Focused on Enhancing Healthcare Operations & Metrics 4Health News:Hanger Orthopedic Group, Inc. Announces First Quarter 2009 Earnings Release Conference Call 2Health News:iVu Imaging Selects BancTec's Multi-Vendor Services Group as Exclusive Service Provider for Intelligent Volumetric Ultrasound Equipment 2Health News:iVu Imaging Selects BancTec's Multi-Vendor Services Group as Exclusive Service Provider for Intelligent Volumetric Ultrasound Equipment 3Health News:Virus evolution topic of Darwin talk at UH April 2 2
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: